logo-loader
HealthMedical technology & services
Q BioMed Inc

Q BioMed, Chemveda to collaborate further on liver cancer treatment

The companies are ramping up production of uttroside-B, a compound shown to be toxic to liver cancer cells

Doctor holding liver model
A 2016 Scientific Reports study found the compound to be 10 times more effective against the HepG2 liver cancer cell line than the then-only liver cancer drug approved by the FDA

Q BioMed Inc (OTCMKTS:QBIO) and India-based Chemveda Life Sciences have formalized their collaboration on a compound engineered to battle liver cancer. 

The companies have been involved in a joint research program since early 2017 to synthesize the compound uttroside-B and study its use for the treatment of liver cancer. 

Uttroside-B, is a potent saponin, a type of chemical compound found in Black Nightshade shrub. Obtaining it can be challenging, but Chemvada developed a method to synthesize it.

Now, the plan is to ramp up production and go forward with pre-clinical testing and clinical trials.

READ: Q BioMed, Chemveda Life Sciences achieve potential chemotherapeutic breakthrough in liver cancer

As part of the deal, Q BioMed will pay Chemveda a mix of cash and stock as well as capped royalty on net sales. Chemveda will have first right of refusal and the right to manufacture any products that come out of the collaboration.

"Chemveda has been an excellent partner in this program, both in terms of execution and problem solving,” Q BioMed CEO Denis Corin said in a statement. “We look forward to the next phase as we advance this promising molecule and others towards the clinic.” 

The companies have reason to be optimistic.

A 2016 Scientific Reports study found the compound to be 10 times more effective against the HepG2 liver cancer cell line than the then-only liver cancer drug approved by the US Food and Drug Administration.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Q BioMed Inc

Price: $0.72

Market: OTCQB
Market Cap: $10.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed successfully synthesizes molecule to treat liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer. Corin says the molecule called...

on 08/20/2019

2 min read